NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will be an invited participant at the 6th DIA / FDA Oligonucleotide-Based Therapeutics Conference to be held September 9-11, 2015 in Washington. This conference is jointly convened by the DIA (Develop Innovate Advance) organization and the US Food and Drug Administration to showcase and educate on advances, safety and challenges in the field of oligonucleotide-based therapeutics.
Replicor will present an overview of mechanism of action and current clinical experience with its nucleic acid polymer (NAP) technology for the treatment of chronic HBV infection and HBV / HDV co-infection.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com and follow us on Twitter @replicorinc.